Evidence map›Paper›PMID 42676636›Full record

ArticleFrontiers in microbiology2026

Disrupted terminal bilirubin catabolism links

Omer Sabti, Ksenia Lialin-Tzadikov, Valeria Ivanova, Mally Dori-Bachash, Shaked Uzi-Gavrilov, Zohar Tik, Roi Mashiach, Alvah Zorea, Itzhak Mizrahi, Arik Segal and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Omer SabtiDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Ksenia Lialin-TzadikovDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Valeria IvanovaDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Mally Dori-BachashDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Shaked Uzi-GavrilovDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Zohar TikDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Roi MashiachDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Alvah ZoreaDepartment of Life Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Itzhak MizrahiDepartment of Life Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel.
Arik SegalDepartment of Gastroenterology, Soroka University Medical Center, Be'er Sheva, Israel.
Keren Moyal-AttiasDepartment of Gastroenterology, Soroka University Medical Center, Be'er Sheva, Israel.
Eran ElinavDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
Michael M MeijlerDepartment of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown. Methods: Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn's disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD). Results: We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted ( Discussion: These findings implicate

Indexed as

bilirubinIBDmetabolomicsmicrobial chemical communicationmicrobiota

Identifiers

PMID42676636
PMCPMC13526984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.